Abstract
Enhancements in the treatment of sexual offenders has been taking place for over four decades. The development of pharmacological therapy has helped to reduce the risk of re-offense and has demonstrated its utility in combination with psychotherapy. However further studies to demonstrate the efficacy of these therapies are required. We conducted a retrospective study in a unit that provides care for sexual offenders (court ordered treatment or voluntary treatment). Among the 224 patients at ERIOS over the past 15 years, we identified 23 patients who had received anti-libidinal treatment (ALM) at some point in their care. The results, obtained from only 22 informative files, indicate that 16 patients presented no notion of deviant fantasy or behavioral relapse under medication. This study also highlights the comorbidities and offers a perspective regarding the improvement in prescribing this type of pharmacological therapy.
Highlights
The use of anti-libidinal medication (ALM), along with psychotherapy, is often considered in the treatment of sexual offenders [13]
In 2014, the Haute Autorité de Santé (HAS, French national authority for health, an independent public authority of a scientific nature) noted the absence of any framework or study to evaluate the efficacy of anti-libidinal medication in the treatment of paraphilia [4]
The Erios unit has three components: Criavs Aquitaine, a resource center for the professionals providing care to sex offenders in Aquitaine; Inter-CD, a mobile care team for the sex offenders incarcerated in the penitentiary establishments in Aquitaine; and Dispo-33, an outpatient unit for sex offenders who were sentenced to a court ordered treatment in Gironde territory
Summary
The use of anti-libidinal medication (ALM), along with psychotherapy, is often considered in the treatment of sexual offenders [13]. In 2014, the Haute Autorité de Santé (HAS, French national authority for health, an independent public authority of a scientific nature) noted the absence of any framework or study to evaluate the efficacy of anti-libidinal medication in the treatment of paraphilia [4]. 10 years ago, some of these medications obtained marketing authorization for use in France [4]: cyproterone acetate, in April 2005 in France for a “reduction of sexual impulses in paraphilia in association with psychotherapeutic care”. It is used for its antiandrogen action.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
